"The Zydus group will market this therapy through Zydus Trans-immune, a division that offers a range of therapies related to transplant medicine," group firm Cadila Healthcare said in a filing to the BSE.
Grafalon offers a specific advantage of efficacy and better safety profile through targeted immunosuppression, it added.
"More than 200,000 patients till date, in over 50 countries, have been treated with Grafalon," Cadila Healthcare said.
"Currently, an estimated 10,000 solid organ transplant and stem cell transplants are taking place annually across 200 plus transplant centres in India," the company said.
Shares in Cadila Healthcare, on Thursday, ended 0.36 per cent lower at Rs 387.20 apiece on the BSE, whose benchmark Sensex index finished down 0.41 per cent.
Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.